GILD Share Price

Open 67.11 Change Price %
High 67.82 1 Day -0.01 -0.01
Low 66.97 1 Week -0.24 -0.35
Close 67.50 1 Month -2.98 -4.23
Volume 5446869 1 Year -24.96 -27.00
52 Week High 103.10
52 Week Low 65.38
GILD Important Levels
Resistance 2 68.29
Resistance 1 67.96
Pivot 67.43
Support 1 67.04
Support 2 66.71
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
ASTI 0.00 0.00%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
MU 28.76 1.16%
MU 28.76 1.16%
MU 28.76 1.16%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.10 100.00%
LOCM 0.09 50.00%
IPXL 12.70 37.30%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
RGLS 1.70 21.43%
SCON 1.54 19.38%
CPRX 2.01 18.24%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
VALV 0.02 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Gilead Sciences, Inc. (NASDAQ: GILD)

GILD Technical Analysis 5
As on 27th Mar 2017 GILD Share Price closed @ 67.50 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 77.70 & Strong Sell for SHORT-TERM with Stoploss of 70.24 we also expect STOCK to react on Following IMPORTANT LEVELS.
GILD Target for March
1st Target up-side 74.8
2nd Target up-side 77.82
3rd Target up-side 80.85
1st Target down-side 66.16
2nd Target down-side 63.14
3rd Target down-side 60.11
GILD Other Details
Segment EQ
Market Capital 51045679104.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.gilead.com
GILD Address
GILD
333 Lakeside Drive
Foster City, CA 94404
United States
Phone: 650-574-3000
Fax: 650-578-9264
GILD Latest News
Interactive Technical Analysis Chart Gilead Sciences, Inc. ( GILD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Gilead Sciences, Inc.
GILD Business Profile
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead�s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company�s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.